Latest Breaking News On - Chosa oncology - Page 1 : comparemela.com

Allarity Therapeutics (ALLR) and FivepHusion Partner to Support Clinical Development of Deflexifol with DRP

Allarity Therapeutics (ALLR) and FivepHusion Partner to Support Clinical Development of Deflexifol with DRP
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomas pedersenChristian toouliMike beyerJamesg cullemAllarity company contactAllarity therapeutics incEuropean society for medical oncologyCarrotize pr communicationsSam brown incFivephusion companyFivephusion clinical collaboration pressExchange commissionSmerud medical research internationalAllarity therapeuticsDetsamma investments

Allarity Therapeutics (ALLR) Prices 2 44M Share Offering at $4 50/sh

Allarity Therapeutics (ALLR) Prices 2 44M Share Offering at $4 50/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesThomas jensenMike beyerThomas pedersenCarrotize pr communicationsSam brown incSmerud medical research internationalA gp alliance global partnersAllarity therapeutics pressCompany contactAllarity therapeutics incExchange commissionAllarity therapeuticsConvertible preferred stockAlliance global partners

Abstract Evaluating Allarity s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

Abstract Evaluating Allarity s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeThomas pedersenMike beyerCarrotize pr communicationsSam brown incAllarity therapeutics incAmerican society of clinical oncologyExchange commissionSmerud medical research internationalCompanion diagnosticCisplatin acceptedStudy evaluatingCisplatin responseCertain breast cancerAllarity therapeutics

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON —. | March 28, 2023

United statesMike beyerThomas pedersenJamesg cullemThomas jensenSmerud medical research internationalSam brown incExchange commissionCarrotize pr communicationsAllarity therapeutics incCompany scientific advisory boardCompany contactAllarity therapeuticsChief executive officerScientific advisory boardChosa oncology

Allarity Therapeutics, Inc : Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a

United statesThomas jensenMike beyerThomas pedersenSmerud medical research internationalSam brown incCarrotize pr communicationsComputershare trust companyExchange commissionAllarity therapeutics incCompany contactCompany board of directors theCommon stock will begin tradingPost split adjusted basisYork timeNasdaq global market